How I reduce and treat posttransplant relapse of MDS
A Mina, PL Greenberg, HJ Deeg - Blood, 2024 - ashpublications.org
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only potentially curative
option for patients with high-risk myelodysplastic syndromes (MDS). Advances in …
option for patients with high-risk myelodysplastic syndromes (MDS). Advances in …
Understanding differential technologies for detection of MRD and how to incorporate into clinical practice
J Cloos, LL Ngai, M Heuser - Hematology, 2023 - ashpublications.org
Patient-and leukemia-specific factors assessed at diagnosis classify patients with acute
myeloid leukemia (AML) in risk categories that are prognostic for outcome. The induction …
myeloid leukemia (AML) in risk categories that are prognostic for outcome. The induction …
Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall …
E Accorsi Buttini, C Doran, M Malagola, V Radici… - Cancers, 2024 - mdpi.com
Simple Summary Allogeneic stem cell transplantation (allo-SCT) represents the only
potentially curative treatment for high-risk acute myeloid leukemia (AML) and …
potentially curative treatment for high-risk acute myeloid leukemia (AML) and …
CD34 Chimerism Directed Donor Lymphocyte Infusion with or without Azacitidine Results in Reduced Relapse and Superior Overall Survival when Full Donor …
JLC Tan, DJ Curtis, J Muirhead, MI Swain… - … Myeloma and Leukemia, 2024 - Elsevier
Background Regular monitoring of CD34 donor chimerism (DC) is a highly sensitive method
of predicting relapse in allogeneic stem cell transplant (alloHSCT) recipients with AML/MDS …
of predicting relapse in allogeneic stem cell transplant (alloHSCT) recipients with AML/MDS …